Literature DB >> 10865915

Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail.

M C Bradley1, S Leidich, N Isham, B E Elewski, M A Ghannoum.   

Abstract

Onychomycosis is a common fungal disease infecting up to 20% of the population over age 40. The major causative agent of onychomycosis is Trichophyton rubrum. Uncontrolled infection may eventually lead to penetration of the newly forming nail plate. In spite of the encouraging cure rate with recent antifungal agents such as the allylamines (terbinafine) and azoles (itraconazole and fluconazole) some patients inevitably fail therapy. In this investigation, a group of patients from a multi-center study designed to assess the efficacy of terbinafine with known cases of onychomycosis were selected for evaluation. Nail samples from this patient group were colonized with T. rubrum throughout the terbinafine therapy. Antifungal susceptibility testing was performed on these T. rubrum isolates to detect change in MIC values. Strain relatedness was examined using random amplified polymorphic DNA (RAPD) technique. Our results revealed failure of patients to clear T. rubrum is not related to the development of resistance to the drug. While species determination was possible, we were not able to identify differences that would indicate reinfection with a new strain. Analysis of patient demographic data revealed that 70% of patients were over 45 years old, 56.6% were previously treated with antifungals, 60% came from family history with onychomycosis and 13% were diabetic. In conclusion, our data indicate that patients' failure to clear onychomycosis was not associated with resistant development. Failure of terbinafine therapy may be dependent on host-related factors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10865915

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  9 in total

1.  Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine.

Authors:  Pranab K Mukherjee; Steven D Leidich; Nancy Isham; Ingrid Leitner; Neil S Ryder; Mahmoud A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

2.  Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years.

Authors:  O Simonetti; M L Bernardini; D Arzeni; A Cellini; F Barchiesi; A Offidani
Journal:  Mycopathologia       Date:  2004-10       Impact factor: 2.574

3.  Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine.

Authors:  Colin S Osborne; Ingrid Leitner; Bettina Hofbauer; Ceri A Fielding; Bertrand Favre; Neil S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 4.  Strain differentiation of dermatophytes.

Authors:  Susan M Abdel-Rahman
Journal:  Mycopathologia       Date:  2008-05-14       Impact factor: 2.574

Review 5.  Onychomycosis: Practical Approaches to Minimize Relapse and Recurrence.

Authors:  Antonella Tosti; Boni E Elewski
Journal:  Skin Appendage Disord       Date:  2016-09-14

6.  In vitro analysis of the ability of Trichophyton rubrum to become resistant to terbinafine.

Authors:  Colin S Osborne; Bettina Hofbauer; Bertrand Favre; Neil S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

7.  In vitro antifungal activity of naftifine hydrochloride against dermatophytes.

Authors:  M Ghannoum; N Isham; A Verma; S Plaum; A Fleischer; B Hardas
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

8.  Phenotypic characterization of Trichophyton rubrum isolates from two geographic locations in Brazil.

Authors:  J I Dos Santos; E J Vicente; C R Paula; W Gambale
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

9.  Fungal nail infections (onychomycosis): a never-ending story?

Authors:  Mahmoud Ghannoum; Nancy Isham
Journal:  PLoS Pathog       Date:  2014-06-05       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.